Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The real annomly in the study is the low placebo. If you insert 72% or 78%(or greater) into the patients that get severe OM for head and neck cancer treatment which is closer to historical rates the numbers for our trial look Awesome.
I call this the Cox effect. They run it up and then sell it quick. Just waiting on secondary end points now.
To the contrary! These were good results. Your hyperbole suggests you over your head.
Thanks great analysis as usual.
I think they have 60 days if I remember correctly.
As we have discussed before I think the 300k number is low because there are a number of other cancer patients that get OM. If we are successful the number could be >500k.
Don't you think this will workout in P's favor because of the history?
That wasn't your point but good try! Most patients just want relief from their symptoms and as long as it's safe and tolerated they don't care.
Unbelievable! Can you imagine any real medical professional saying or suggesting something like that?
Never mind
He's right your wrong. The more severe the less waxing and waning.
Perfect. Thanks
Good question. If they do get a partnership before P how much would you sell of your holdings?
Pretty much par for the course.
It's like the 3 little bears: to hot to cold but in this case it's never right! The PR nit picking is so over done.
LMAO! The PR is to boring, it's to fluffy, there to repetitive, Leo underlines sentences, no it's just Leo giving shareholders information.
complete BS as usual! He has plenty of money for a B-OM or B-UP phase 3 trial but that's not his plan. They have been very clear about partnerships.
What's next:Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results
DP, what's your take on P? Thanks
The usual noise on a slow day! Yawn!
Check out slcimmuno post #204798
She and others have proven with timelines they the hit pieces did have an impact.
Amen! Drop the mic
Of course it's always the "skeptical of management" argument. It's difficult to talk about the science but very easy for one to second guess management decisions.
It's apparent that some are feeling desperate and can't criticize the science so now they have chosen to go after the messenger. Sad! Desperate!
No science no company! Period! Biotech companies are always dealing with trade offs. If you don't like the company or the science just find one you do like. I think the vast majority love the science info and appreciate the effort.
There is zero chance Leo will pr any B-OM news today.
Awesome! Happy thanksgiving to you and all the longs here!
B-OM top line results due any day!Breakthrough designation and partnership soon after!
Hey this is biotech! It's not if, it's when there will be delays. So if you don't like it move on!
Yawn! Thanks for nothing!
Investing in a biotech is a long term investment. Always spend most of your time looking at the science. Is the company progress? If so have patience but don't be bitter about the pps it will probably go up and down. If you don't like the science then finding an alternative investment would be a good idea.
I agree Leo has almost never put out info on a Holiday week.
Knowing who is shorting a biotech would be an excellent idea and makes complete sense. If someone thinks they have a reasoned argument fine but enough of the anonymous bs.
No one knows for sure what the pps will be but what we do know is that it will give the company and the pipeline some 3rd party validation. Then a great shot at uplisting. Then more partnerships etc etc. I think the first deal is the hardest and most important.
When someone is wrong over and over it creates a creditability gap.
Yes and blinded by the light...thanks for the great science posts.
Science is 95% of the game right now. Without the science there are no potential deals. The focus must be and should be on the science.
Omg! The calories burned parsing words today could light a 3rd world country!